Headlines about Orthofix International (NASDAQ:OFIX) have been trending somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Orthofix International earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 46.5099264559027 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news stories that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

Shares of Orthofix International stock opened at $59.56 on Thursday. The company has a market capitalization of $1,092.89, a PE ratio of 180.49, a PEG ratio of 3.34 and a beta of 0.24. Orthofix International has a 1 year low of $36.10 and a 1 year high of $61.00.

Orthofix International (NASDAQ:OFIX) last released its quarterly earnings results on Monday, February 26th. The medical device company reported $0.52 EPS for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.02. The company had revenue of $116.90 million for the quarter, compared to analyst estimates of $116.93 million. Orthofix International had a return on equity of 10.66% and a net margin of 1.43%. Orthofix International’s revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.42 earnings per share. equities research analysts predict that Orthofix International will post 1.84 earnings per share for the current fiscal year.

A number of brokerages have issued reports on OFIX. TheStreet upgraded Orthofix International from a “c+” rating to a “b” rating in a report on Tuesday. BidaskClub upgraded Orthofix International from a “hold” rating to a “buy” rating in a report on Friday, March 16th. Gabelli restated a “buy” rating on shares of Orthofix International in a report on Wednesday, February 28th. SunTrust Banks raised their target price on Orthofix International to $67.00 and gave the stock a “buy” rating in a report on Monday, March 5th. Finally, ValuEngine upgraded Orthofix International from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Orthofix International has a consensus rating of “Buy” and a consensus price target of $57.42.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/03/22/orthofix-international-ofix-receives-daily-media-impact-rating-of-0-21.html.

About Orthofix International

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Insider Buying and Selling by Quarter for Orthofix International (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.